United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

aspen pharma trading ltd - tioguanine - oral tablet - 40mg

Israel - English - Ministry of Health

perrigo israel agencies ltd, israel - thioguanine - tablets - thioguanine 40 mg - tioguanine - tioguanine - acute nonlymphocytic leukemia.

Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - tioguanine bp - tablet - tioguanine bp 40 mg - antineoplastic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - tioguanine, quantity: 40 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; stearic acid; magnesium stearate; potato starch; acacia - indications as at 10 october 2005: acute myeloblastic leukaemia. less commonly, chronic granulocytic (myelocytic, myeloid, myelogenous) leukaemia. although superior results are generally obtained with busulphan (myleran) in the treatment of chronic granulocytic leukaemia. lanvis may be useful during blast crises or periods of thrombocytopenia induced by busulphan or other therapy. a degree of cross resistance exists between lanvis (thioguanine) and puri-nethol (mercaptopurine) and generally it is not to be expected that patients who no longer respond to mercaptopurine will respond to thioguanine or vice versa. unlike mercaptopurine the detoxification of lanvis is not dependent on xanthine oxidase, hence therapy with lanvis is not affected by the xanthine oxidase inhibitor, allopurinol (zyloprim). recent evidence suggests that lanvis is particularly useful in concurrent or sequelist combination with other antineoplastic drugs, e.g., cytosine arabinoside. not effective for the treatment of chronic lymphocytic l

United States - English - NLM (National Library of Medicine)

aspen global inc. - thioguanine (unii: ftk8u1gznx) (thioguanine anhydrous - unii:wix31zpx66) - thioguanine 40 mg - tabloid brand thioguanine is indicated for remission induction and remission consolidation treatment of acute nonlymphocytic leukemias. however, it is not recommended for use during maintenance therapy or similar long-term continuous treatments due to the high risk of liver toxicity (see warnings and adverse reactions). the response to this agent depends upon the age of the patient (younger patients faring better than older) and whether thioguanine is used in previously treated or previously untreated patients. reliance upon thioguanine alone is seldom justified for initial remission induction of acute nonlymphocytic leukemias because combination chemotherapy including thioguanine results in more frequent remission induction and longer duration of remission than thioguanine alone. tabloid brand thioguanine is not effective in chronic lymphocytic leukemia, hodgkin’s lymphoma, multiple myeloma, or solid tumors. although thioguanine is one of several agents with activity in the treatment of the chronic phase of

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - tioguanine - oral capsule - 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - tioguanine - oral tablet - 40mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - tioguanine - oral suspension - 10mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - tioguanine - oral tablet - 40mg

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - tioguanine 40mg - tablet - 40 mg - active: tioguanine 40mg excipient: acacia lactose monohydrate magnesium stearate potato starch stearic acid - lanvis is indicated primarily for the treatment of acute leukaemias especially:- · acute myelogenous leukaemia · acute lymphoblastic leukaemia